Merck Beats Quarterly Estimates on Keytruda Strength, Narrows Outlook

Merck reported stronger-than-expected quarterly earnings, driven by robust sales of its cancer drug Keytruda and other new products, surpassing both top-line and bottom-line estimates. However, the pharmaceutical giant also narrowed its full-year financial outlook.